MarketsandMarkets Biomarker and Companion Diagnostics Conference

3 - 4 October 2019 | Radisson Blu Edwardian, Grafton Hotel, London
CONFERENCE SPEAKERS
Advisors
Thomas Joos
Thomas Joos
Deputy Managing Director,
University of Tübingen


Dr. Thomas Joos joined 1998 the NMI at the University of Tuebingen heading the department of biochemistry. Since 2013 he is the deputy managing director of NMI. His research is focused on miniaturized multiplexed immunoassays for biomarker research and diagnostic applications. Dr. Joos studied Biochemistry at the University of Tubingen. He performed his Ph.D. degree in 1995 on integrin‐alpha5 during early embroygenesis of Xenopus laevis in the laboratory of Prof. Peter Hausen at the Max‐Planck‐Institute of Developmental Biology. Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "Plasma Proteome Institute" Washington, DC, USA, and of Myriad‐RBM, Austin, TX, USA. Dr. Joos is co-founder of SIGNATOPE, Reutlingen, Germany, a protein biomarker company offering assay development and screening services for any protein in any species.


Speakers
Shailendra Singh (Shelly)
Shailendra Singh (Shelly)
Chief Operating Officer,
MarketsandMarkets


Shailendra Singh (Shelly) is Chief Operating Officer of MnM and a member of its board. He focuses on global sales and client services functions, as well as commercial optimization at MarketsandMarkets. He has years of expe¬rience in global delivery and outsourcing sector in the IT/ Consulting/Analytics/Big Data sectors. Prior to MnM, he was leading the global sales, client services and commercial ef¬fectiveness functions for Mu Sigma, a unicorn company and a leading global provider of Decision Sciences and Big Data analytics solutions.


Dr. Ian Pike
Dr. Ian Pike
Chief Scientific Officer,
Proteome Sciences PLC


Ian Pike’s biography Ian Pike is the Chief Scientific Officer at Proteome Sciences and has 30 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Welcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialization of a wide portfolio of technologies related to the biomedical sector. Ian also worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA. Since joining Proteome Sciences in 2002 he has held a number of roles covering intellectual property management, business development, operational management and is now focused on leading the Company’s scientific strategy to offer clients a flexible, high quality service.


Stephanie Traub
Stephanie Traub
Biomaker Development Specialist,
Cancer Research UK



Thomas Joos
Thomas Joos
Deputy Managing Director,
University of Tübingen


Dr. Thomas Joos joined 1998 the NMI at the University of Tuebingen heading the department of biochemistry. Since 2013 he is the deputy managing director of NMI. His research is focused on miniaturized multiplexed immunoassays for biomarker research and diagnostic applications. Dr. Joos studied Biochemistry at the University of Tubingen. He performed his Ph.D. degree in 1995 on integrin‐alpha5 during early embroygenesis of Xenopus laevis in the laboratory of Prof. Peter Hausen at the Max‐Planck‐Institute of Developmental Biology. Dr. Joos is a member of the editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "Plasma Proteome Institute" Washington, DC, USA, and of Myriad‐RBM, Austin, TX, USA. Dr. Joos is co-founder of SIGNATOPE, Reutlingen, Germany, a protein biomarker company offering assay development and screening services for any protein in any species.


Dan Sikkema
Dan Sikkema
Vice President,
Quanterix


Dr. Sikkema is currently Vice President, Accelerator and Pharma services for Quanterix       Corporation.

Dan brings 25 years’ experience in the biopharmaceutical, vaccine and cell/gene therapy fields supporting oncology, neurosciences, respiratory, immunology and infectious disease. He has held positions of increasing responsibility at Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, Frontage Laboratories and GlaxoSmithKline.  In his career, he has contributed to the licensure of Prev(e)nar, Meningitec, Gardasil, RotaTeq, ProQuad, Zostavax, and Dengue vaccines, also Ofatumumab, Raxibacumab, Benlysta, Albiglutide, Mepolizumab, Denosumab, and other biopharmaceuticals, as well as Strimvelis (the world’s first ex vivo cell/gene therapy product). He has also worked with the World Health Organization, National Institute for Biological Standards and Controls (NIBSC), US Centers for Disease Control, FDA and EMA in roles as an invited expert and as an advisor. Dr. Sikkema earned his PhD in Microbiology and Public Health from Michigan State University, College of Medicine. He was a Post-Doctoral Fellow in Infectious Diseases at SUNY at Buffalo, School of Medicine.  He has Chaired Division V (Clinical and Diagnostic Immunology) for American Society for Microbiology and was Coordinator for an Innovative Medicine Initiative project ABIRISK, the largest funded project to study Immunogenicity of Biotherapeutics.  He has authored 30 peer-reviewed publications and has delivered more than 80 public presentations globally at scientific symposia.


Peter Parker
Peter Parker
Director of the CRUK KHP Centre and Professor of Cancer Cell Biology,
KCL


Peter Parker trained in Biochemistry (BA) at Oxford and then as a post-graduate under Professor Sir Philip Randle in Clinical Biochemistry (D.Phil) at Oxford. He won an MRC Fellowship to work with Professor Sir Philip Cohen and then worked in oncology with Professor Mike Waterfield, subsequently moving as a founder member to the Ludwig Institute at UCL. In 1990 he was appointed at the ICRF which become the London Research Institute (LRI) and then moved into the newly founded Francis Crick Institute in 2015 as a Senior Group Leader. Peter has held a joint appointment with King’s College London since 2006 where he is currently Director of the CRUK KHP Centre. Peter Parker has published over 350 primary articles in the area of signal transduction. Through the founding of companies (PIramed, Symansis, FASTBASE Solutions) he has also pursued translational interests in the areas of cancer drug development and biomarkers.


Dr. Richardus Vonk
Dr. Richardus Vonk
VP, Head Oncology Statistics and Data Management,
Bayer AG



Yong-Jie Lu
Yong-Jie Lu
Professor of Molecular Oncology (Barts Cancer Institute),
Queen Mary University of London (QMUL)


Professor Yong-Jie Lu is a professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London. His past work has been mainly focused on identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. Recently, his research work moved into circulating biomarker development, aiming to translate them into cancer diagnosis, prognosis and therapeutic stratification. He published more than 100 peer reviewed original studies, in journals including Lancet, PNAS, Nature Genetics, Journal Clinical Oncology, Cancer Research and Clinical Cancer Research. He also published several review articles and book chapters. His finding in circulating tumour and other cell biomarkers have been reported as research news in multiple national and international media, including TV, radio, newspaper and online news media. He has filled two patent applications for prostate cancer prognosis using circulating cell biomarkers. He has been serving as editorial board members for a number of international scientific journals.


Tony Whetton
Tony Whetton
Professor of Cancer Cell Biology,
University of Manchester


Professor Tony Whetton is currently the Director of the Stoller Biomarker Discovery Centre. He also has a programme of leukaemia research based at the Wolfson Molecular Imaging Centre, Christie Hospital. He obtained a PhD in signal transduction research and biophysical chemistry. This was followed by research into membrane structure using electron spin resonance techniques. He then moved into a completely different field of experimental haematology at the Paterson Institute. He left this position to take up a lectureship at UMIST in 1984 where he became the Professor of Cell Biology in 1995 and Head of Department in 200 He joined the School of Medicine at the University of Manchester in 2003 as Professor of Cancer Cell Biology, based at the Christie Hospital. Here he has established a state of the art biological mass spectrometry facility for stem cell and leukaemia research. This research has expanded and developed to include a clinical proteomics research capability, where the objective is to discover new biomarkers associated with the cancers leading to the development of the £26 million Stoller Biomarker Discovery Centre which uses proteomics and informatics to define disease mechanisms and biomarkers.


Shanon Seger
Shanon Seger
Scientist - Imaging Specialist,
Roche


Shanon Seger is a digital pathology imaging specialist at Roche Pharmaceuticals. Shanon’s interest are providing quantitative and reproducible image analysis data and digital pathology solutions to support the understanding of pathology and uncover drugs mechanism of action. Shanon holds a bachelor degree in physiology and a master degree in developmental biology from the University of Strasbourg. She first worked at Novartis Pharmaceuticals in Basel within the neuroscience department where she focused on the development of confocal imaging protocols combined with automated image analysis assays. She then joined Actelion pharmaceuticals to focus on whole slide imaging and to support the development of the in-house image analysis software ORBIT.  She currently works at Roche within the digital pathology group where she actively works on the implementation of a LIS system to fully digitalize the lab and develops automated image analysis assays to the pathologists and the different disease areas.


Louis Levy
Louis Levy
Director of Corporate and Business Development,
Ultivue



Dr. Bevin Gangadharan
Dr. Bevin Gangadharan
Research Associate,
University of Oxford


Dr. Bevin Gangadharan is a research scientist in Professor Nicole Zitzmann’s lab in the Department of Biochemistry at the University of Oxford. He did his DPhil in Professor Zitzmann’s lab where he used proteomics to identify novel serum biomarker candidates for liver fibrosis in hepatitis C patients. More recently he has helped to discover novel NAFLD biomarkers which are patented. Before joining the Zitzmann group he obtained his BSc in Medical Biochemistry at the University of Surrey which included a sandwich year at GlaxoSmithKline where he used proteomics techniques and looked at ways of improving the representation of low abundant plasma proteins which helps with biomarker discovery. Bevin is also on the editorial board for Biomarker Research (an Open Access publication by BioMed Central).


Nicola Curtin
Nicola Curtin
Professor of Experimental Therapeutics,
Newcastle University


Nicola Curtin is Professor of Experimental Cancer Therapeutics at Newcastle University, UK. Her research has focussed on the development and therapeutic potential of drugs targeting the DNA damage response (DDR): She was a key member of the team that discovered the PARP inhibitor, rucaparib (Rubraca®), and was first to propose (March 2002) the therapeutic potential of PARP inhibitors in BRCA-related cancer. She was the first to demonstrate the synergy between PARP inhibition and ATR inhibitors in 201 Her translational studies involve the development of predictive biomarkers for patient stratification and pharmacodynamic biomarkers to monitor the activity of drugs. Her group was the first to identify (in 2011) that >50% of ovarian cancers are defective in homologous recombination DNA repair using a functional biomarker. She is an inventor on 16 patents, an author of over 150 peer-reviewed publications and editor of 2 books. (Google scholar h-index = 63, citations =16,908)


Dr. Paul J. Skipp
Dr. Paul J. Skipp
Associate Professor/Centre Director, Centre for Proteomic Research,
University of Southampton



Dr. Sikha Saha
Dr. Sikha Saha
Associate Professor of Cardiovascular and Cerebrovascular Medicine,
University of Leeds



Dr. Susan Astley
Dr. Susan Astley
Division of Informatics, Imaging & Data Sciences,
University of Manchester



Pierre Arsene
Pierre Arsene
Co-Founder & CEO,
Mursla


Pierre Arsène is an entrepreneur in deeptech and co-founder & CEO of Mursla Ltd, a Cambridge-based cancer liquid biopsy company. He is an ex-Visiting Researcher at the department of Physics (Cavendish) of the University of Cambridge where he focused on nanosensors and dielectrophoresis research. Prior to this, he was senior Vice President at J.P. Morgan after having spent 10 years in Investment Banking / M&A mostly covering the biotech sector across the world. He advised companies such as Roche, Siemens or Daiichi Sankyo on biotech acquisitions, commercialization and pipeline optimization while managing a team of 25 people. He graduated from HEC Paris Grande Ecole with a MSc. in Management after a classe préparatoire in mathematics.


Celine Pallaud
Celine Pallaud
Executive Director, Oncology Precision Medicine Hematology DA Lead,
Novartis



Eithne Costello-Goldring
Eithne Costello-Goldring
Professor of Molecular Oncology,
University of Liverpool



Mario Richter
Mario Richter
Associate Director Large Molecule and Biomarker,
Abbvie (tentative)



Prof. Gin Jose
Prof. Gin Jose
Chair in Functional Materials,
University of Leeds



Dr. Bernadett Szabados
Dr. Bernadett Szabados
Clinical Research Associate,
Barts Cancer Institute



Ned Sherry
Ned Sherry
Manager, Research and Business Development,
Adaptive Biotechnologies